FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311448126> ?p ?o ?g. }

• W4311448126 endingPage "e1206" @default.
• W4311448126 startingPage "e1193" @default.
• W4311448126 abstract "Background and Objectives Patients with spinal cord injury (SCI) commonly experience central neuropathic pain (CNeP), which is challenging to treat. Mirogabalin is effective for peripheral neuropathic pain, but evidence for CNeP is lacking. Methods This randomized, double-blind, placebo-controlled, phase 3 study investigated mirogabalin efficacy and safety for the treatment of CNeP in patients with traumatic SCI. Adult patients from 120 sites throughout Japan, Korea, and Taiwan were randomized (1:1) to receive placebo or mirogabalin (5 mg twice daily [BID] for 1 week, 10 mg BID for 1 week, and 10 or 15 mg BID for 12 weeks). Patients with moderate renal impairment received half the dosage. The primary efficacy endpoint was change from baseline in the weekly average daily pain score (ADPS) at week 14. The secondary endpoints included ADPS responder rates, the Short-Form McGill Pain Questionnaire (SF-MPQ), average daily sleep interference score (ADSIS), and Neuropathic Pain Symptom Inventory (NPSI). Adverse events were monitored for safety. Results Each treatment group comprised 150 patients. Mirogabalin elicited a statistical and clinically relevant improvement in change from baseline in the weekly ADPS at week 14 (least-squares mean difference [95% CI] vs placebo −0.71 [−1.08 to −0.34], p = 0.0001). Responder rates at week 14 were higher for mirogabalin than those for placebo (odds ratio [95% CI] 1.91 [1.11–3.27] for the ≥30% responder rate; 2.52 [1.11–5.71] for the ≥50% responder rate). Statistical improvements (i.e., least-squares mean difference [95% CI] vs placebo) were also observed in the SF-MPQ (−2.4 [−3.8 to −1.1]), ADSIS −0.71 (−1.04 to −0.38), and NPSI −7.7 (−11.1 to −4.4) scores. Most treatment-emergent adverse events were mild; no serious adverse drug reactions were reported. Discussion Mirogabalin elicited clinically relevant decreases in pain and was well tolerated, suggesting that mirogabalin is a promising treatment for patients with CNeP due to SCI. Trial Registration Information ClinicalTrials.gov (NCT03901352); first submitted April 3, 2019; first patient enrolled March 14, 2019; available at clinicaltrials.gov/ct2/show/NCT03901352. Classification of Evidence This study provides Class I evidence that in adult patients with CNeP due to traumatic SCI, mirogabalin, 10 or 15 mg BID, effectively improves weekly ADPS at week 14." @default.
• W4311448126 created "2022-12-26" @default.
• W4311448126 creator A5000173409 @default.
• W4311448126 creator A5000501453 @default.
• W4311448126 creator A5006410083 @default.
• W4311448126 creator A5008361611 @default.
• W4311448126 creator A5013735486 @default.
• W4311448126 creator A5019715599 @default.
• W4311448126 creator A5029632592 @default.
• W4311448126 creator A5044341553 @default.
• W4311448126 creator A5048240972 @default.
• W4311448126 creator A5054662687 @default.
• W4311448126 creator A5076053645 @default.
• W4311448126 creator A5081503393 @default.
• W4311448126 creator A5083701668 @default.
• W4311448126 date "2023-03-14" @default.
• W4311448126 modified "2023-10-18" @default.
• W4311448126 title "Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury" @default.
• W4311448126 cites W1892480459 @default.
• W4311448126 cites W1972544335 @default.
• W4311448126 cites W2005540257 @default.
• W4311448126 cites W2038826804 @default.
• W4311448126 cites W2094310013 @default.
• W4311448126 cites W2094528068 @default.
• W4311448126 cites W2113154361 @default.
• W4311448126 cites W2132309748 @default.
• W4311448126 cites W2138407894 @default.
• W4311448126 cites W2152802140 @default.
• W4311448126 cites W2514134797 @default.
• W4311448126 cites W2605420852 @default.
• W4311448126 cites W2801283094 @default.
• W4311448126 cites W2902029082 @default.
• W4311448126 cites W2906590066 @default.
• W4311448126 cites W2912056231 @default.
• W4311448126 cites W2912943392 @default.
• W4311448126 cites W2914845997 @default.
• W4311448126 cites W2917259870 @default.
• W4311448126 cites W2933544291 @default.
• W4311448126 cites W2999283334 @default.
• W4311448126 cites W3023007364 @default.
• W4311448126 cites W3030218829 @default.
• W4311448126 cites W3037975981 @default.
• W4311448126 cites W3089242297 @default.
• W4311448126 cites W3128072664 @default.
• W4311448126 cites W3154664716 @default.
• W4311448126 cites W2130811229 @default.
• W4311448126 doi "https://doi.org/10.1212/wnl.0000000000201709" @default.
• W4311448126 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36517235" @default.
• W4311448126 hasPublicationYear "2023" @default.
• W4311448126 type Work @default.
• W4311448126 citedByCount "5" @default.
• W4311448126 countsByYear W43114481262023 @default.
• W4311448126 crossrefType "journal-article" @default.
• W4311448126 hasAuthorship W4311448126A5000173409 @default.
• W4311448126 hasAuthorship W4311448126A5000501453 @default.
• W4311448126 hasAuthorship W4311448126A5006410083 @default.
• W4311448126 hasAuthorship W4311448126A5008361611 @default.
• W4311448126 hasAuthorship W4311448126A5013735486 @default.
• W4311448126 hasAuthorship W4311448126A5019715599 @default.
• W4311448126 hasAuthorship W4311448126A5029632592 @default.
• W4311448126 hasAuthorship W4311448126A5044341553 @default.
• W4311448126 hasAuthorship W4311448126A5048240972 @default.
• W4311448126 hasAuthorship W4311448126A5054662687 @default.
• W4311448126 hasAuthorship W4311448126A5076053645 @default.
• W4311448126 hasAuthorship W4311448126A5081503393 @default.
• W4311448126 hasAuthorship W4311448126A5083701668 @default.
• W4311448126 hasBestOaLocation W43114481262 @default.
• W4311448126 hasConcept C118552586 @default.
• W4311448126 hasConcept C126322002 @default.
• W4311448126 hasConcept C142724271 @default.
• W4311448126 hasConcept C168563851 @default.
• W4311448126 hasConcept C197934379 @default.
• W4311448126 hasConcept C203092338 @default.
• W4311448126 hasConcept C204787440 @default.
• W4311448126 hasConcept C27081682 @default.
• W4311448126 hasConcept C2777107010 @default.
• W4311448126 hasConcept C2778334475 @default.
• W4311448126 hasConcept C2780775167 @default.
• W4311448126 hasConcept C42219234 @default.
• W4311448126 hasConcept C71924100 @default.
• W4311448126 hasConceptScore W4311448126C118552586 @default.
• W4311448126 hasConceptScore W4311448126C126322002 @default.
• W4311448126 hasConceptScore W4311448126C142724271 @default.
• W4311448126 hasConceptScore W4311448126C168563851 @default.
• W4311448126 hasConceptScore W4311448126C197934379 @default.
• W4311448126 hasConceptScore W4311448126C203092338 @default.
• W4311448126 hasConceptScore W4311448126C204787440 @default.
• W4311448126 hasConceptScore W4311448126C27081682 @default.
• W4311448126 hasConceptScore W4311448126C2777107010 @default.
• W4311448126 hasConceptScore W4311448126C2778334475 @default.
• W4311448126 hasConceptScore W4311448126C2780775167 @default.
• W4311448126 hasConceptScore W4311448126C42219234 @default.
• W4311448126 hasConceptScore W4311448126C71924100 @default.
• W4311448126 hasIssue "11" @default.
• W4311448126 hasLocation W43114481261 @default.
• W4311448126 hasLocation W43114481262 @default.
• W4311448126 hasLocation W43114481263 @default.
• W4311448126 hasOpenAccess W4311448126 @default.

• next